From Curcumin to Seaweed Extracts: Are Phytochemicals the Next Adjunct Therapy in Canine Chronic Enteropathy?

Managing canine chronic inflammatory enteropathy (CIE) often requires veterinarians to balance multiple therapeutic goals simultaneously controlling inflammation, restoring intestinal barrier function, improving microbiota balance, and maintaining long-term tolerability. While elimination diets, immunosuppressants and microbiota-based therapies dominate conventional management strategies, growing attention is now being directed toward naturally derived bioactive compounds. 

Phytochemicals and phycochemicals, bioactive substances derived from plants and algae—are increasingly being investigated for their anti-inflammatory, antioxidant and immunomodulatory properties^1,2,3. 

Although research in dogs remains limited, evidence from experimental intestinal disease models and preliminary canine studies suggests these compounds may eventually become valuable adjuncts in CIE management. 

Why Natural Bioactive Compounds Are Gaining Attention 

CIE is characterised by persistent intestinal immune activation, oxidative stress, and epithelial injury. Conventional therapies such as corticosteroids can be effective, but long-term administration often raises concerns regarding adverse effects and immunosuppression¹. 

This therapeutic gap has encouraged exploration into compounds capable of modulating inflammation through alternative pathways. 

Unlike broad immunosuppressive drugs, many phytochemicals appear to target specific inflammatory mediators while simultaneously supporting mucosal healing and microbial homeostasis^1,4,5,6. 

For veterinarians, this represents an attractive possibility: achieving biologically meaningful intestinal modulation with potentially fewer systemic consequences. 

Curcumin: More Than a Nutraceutical Trend 

Among all phytochemicals discussed in the review, curcumin is arguably the most extensively studied. 

Derived from Curcuma longa, curcumin possesses potent anti-inflammatory properties largely attributed to its ability to inhibit nuclear factor kappa B (NF-κB), a major regulator of inflammatory cytokine production¹. 

By interfering with NF-κB activation, curcumin can suppress proinflammatory mediators including: 

• TNF-α  

• IL-1β  

• IL-2  

• IL-12¹ 

Additionally, curcumin has demonstrated antimicrobial activity against organisms such as Escherichia coli and Salmonella typhimurium¹. 

In murine inflammatory bowel disease models, both oral and systemic administration of curcumin improved survival rates and reduced disease severity scores. The review also highlights encouraging findings from paediatric human IBD studies, where curcumin supplementation alongside standard therapy was associated with improved clinical outcomes¹. 

For veterinarians, the significance lies not simply in curcumin’s popularity as a supplement, but in its multi-target biological activity. In a disease as complex as CIE, therapies capable of simultaneously influencing inflammation, microbial balance and oxidative stress may hold particular relevance. 

Fucoidans: Seaweed-Derived Modulators of Inflammation 

Seaweed-derived compounds are another emerging area of interest. 

Fucoidans are sulfated polysaccharides found primarily in brown algae species. Their biological activity appears closely linked to molecular structure, sulfate content and molecular weight¹. 

One of the most clinically intriguing mechanisms of fucoidans is their ability to inhibit inflammatory cell migration through blockade of P- and L-selectins. In experimental dextran sulfate sodium (DSS)-induced colitis models, fucoidan pretreatment reduced leukocyte infiltration, mucosal injury, and crypt destruction¹. 

Beyond anti-inflammatory effects, fucoidans may also strengthen intestinal barrier integrity by increasing expression of tight-junction proteins such as claudin-1¹. 

Notably, canine-specific data are beginning to emerge. In an ex vivo study involving intestinal tissue explants from dogs with CIE, exposure to fucoidan extract derived from Ascophyllum nodosum resulted in reduced mRNA expression of proinflammatory cytokines TNF-α and IL-15¹. 

Although clinical application remains preliminary, these findings suggest that marine-derived compounds may influence intestinal inflammation at the molecular level. 

Palmitoylethanolamide (PEA): Targeting Neuroimmune Inflammation 

Another fascinating compound discussed in the review is palmitoylethanolamide (PEA), a naturally occurring fatty acid ethanolamide found in legumes and certain vegetables^1,7. 

PEA functions as a prohomeostatic mediator capable of regulating both immune and neuroimmune activity. Its mechanisms appear to involve cannabinoid receptors and peroxisome proliferator-activated receptor-alpha (PPAR-α) pathways^1,8. 

Experimental studies in mice demonstrated that PEA administration reduced intestinal inflammation while helping normalise intestinal motility¹. 

This is particularly interesting given the growing recognition of neuroimmune interactions in chronic GI disease. In some dogs with CIE, abnormal motility and visceral hypersensitivity may contribute significantly to persistent clinical signs. 

A Promising Field—But Not Yet Standard Therapy 

Despite encouraging experimental findings, the review appropriately emphasises that evidence supporting phytochemical and phycochemical use in canine CIE remains limited. 

Most current data arise from: 

• murine colitis models  

• laboratory investigations  

• ex vivo canine tissue studies  

• human IBD research  

Large-scale controlled veterinary clinical trials are still lacking. 

Nevertheless, these compounds represent more than alternative medicine trends. They reflect a broader evolution in gastroenterology toward therapies capable of modulating inflammation, oxidative stress, barrier integrity and microbiota interactions simultaneously. 

For veterinarians treating chronic enteropathy, phytochemicals may not yet replace established therapies, but they are rapidly becoming impossible to ignore.

References 

1. Isidori M, Corbee RJ, Trabalza-Marinucci M. Nonpharmacological treatment strategies for the management of canine chronic inflammatory enteropathy—A narrative review. Veterinary Sciences. 2022 Jan 20;9(2):37. https://www.mdpi.com/2306-7381/9/2/37 

2. Ganesan AR, Tiwari U, Rajauria G. Seaweed nutraceuticals and their therapeutic role in disease prevention. Food Science and Human Wellness. 2019 Sep 1;8(3):252-63. https://www.sciencedirect.com/science/article/pii/S2213453019300254 

3. Xiao J, Bai W. Bioactive phytochemicals. Critical reviews in food science and nutrition. 2019 Mar 26;59(6):827-9. https://www.tandfonline.com/doi/pdf/10.1080/10408398.2019.1601848 

4. Ganesan AR, Tiwari U, Rajauria G. Seaweed nutraceuticals and their therapeutic role in disease prevention. Food Science and Human Wellness. 2019 Sep 1;8(3):252-63. https://www.sciencedirect.com/science/article/pii/S2213453019300254 

5. Xiao J, Bai W. Bioactive phytochemicals. Critical reviews in food science and nutrition. 2019 Mar 26;59(6):827-9. https://www.tandfonline.com/doi/pdf/10.1080/10408398.2019.1601848 

6. Kunnumakkara AB, Bordoloi D, Padmavathi G, Monisha J, Roy NK, Prasad S, Aggarwal BB. Curcumin, the golden nutraceutical: multitargeting for multiple chronic diseases. British journal of pharmacology. 2017 Jun;174(11):1325-48. https://bpspubs.onlinelibrary.wiley.com/doi/pdfdirect/10.1111/bph.13621 

7. Peritore AF, Siracusa R, Crupi R, Cuzzocrea S. Therapeutic efficacy of palmitoylethanolamide and its new formulations in synergy with different antioxidant molecules present in diets. Nutrients. 2019 Sep 11;11(9):2175. https://www.mdpi.com/2072-6643/11/9/2175 

8. Borrelli F, Romano B, Petrosino S, Pagano E, Capasso R, Coppola D, Battista G, Orlando P, Di Marzo V, Izzo AA. Palmitoylethanolamide, a naturally occurring lipid, is an orally effective intestinal anti‐inflammatory agent. British journal of pharmacology. 2015 Jan;172(1):142-58. https://bpspubs.onlinelibrary.wiley.com/doi/pdf/10.1111/bph.12907